MOTS-C (20 mg Vial) Dosage Protocol

MOTS-C (20 mg Vial) Dosage Protocol

Quickstart Highlights

MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation[1][2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline[1][4]. No clinical trials have been completed in humans to date[8]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
  • Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
  • Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days for best potency.
MOTS-C Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 200 mcg (0.2 mg) 3 units (0.03 mL)
Weeks 3–4 400 mcg (0.4 mg) 6 units (0.06 mL)
Weeks 5–6 600 mcg (0.6 mg) 9 units (0.09 mL)
Weeks 7–8 800 mcg (0.8 mg) 12 units (0.12 mL)
Weeks 9–10+ 1,000 mcg (1.0 mg) 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously[7]. Stay at each dose level for approximately 2 weeks before increasing, and monitor for any adverse reactions[7].

For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake vigorously).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 7 days for optimal potency[7].

Important: This guide is for educational purposes only and is not medical advice.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (MOTS-C, 20 mg each):

    • 8 weeks ≈ 2 vials
    • 12 weeks ≈ 3 vials
    • 16 weeks ≈ 5 vials
  • Insulin Syringes (U‑100):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
MOTS-C Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence[1][2][4].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 200–1,000 mcg daily with gradual titration over 10 weeks.
  • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach based on animal-to-human extrapolation.

  • Start: 200 mcg daily for 2 weeks.
  • Titration: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
  • Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated[7].
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality and potency.

  • Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); peptide degrades rapidly at room temperature (~25% activity loss after 24 hours at 4 °C)[7]. Use within 7 days for best potency.
  • Aliquoting: Prepare single-use aliquots and freeze at −20 °C (−4 °F) if needed; avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container[11].
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy[11].
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose, injection site, and any observations to maintain consistency.
  • Discontinue use and consult a medical professional if any concerning symptoms arise.

How This Works

MOTS-c functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise[2]. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog)[1][2]. Activated AMPK shifts cells into an energy-efficient mode – enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis[2].

MOTS-c can also translocate to the cell nucleus under stress conditions and upregulate antioxidant and stress-response genes[2]. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-c may also modulate mTOR and inflammatory pathways, contributing to lifespan and healthspan effects[10]. Its actions resemble those of exercise and metformin at a cellular level[2], making it of great interest for metabolic disorders, obesity, and aging research.

Potential Benefits & Side Effects

Observations from preclinical literature (no human clinical trials completed to date)[8]:

  • Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; prevents diet-induced insulin resistance[1][7].
  • Weight & Fat Reduction: Prevents obesity and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation[1][7].
  • Post-Menopausal Metabolism: Mitigates metabolic decline in ovariectomized mice; prevents menopause-related fat gain and insulin resistance[3].
  • Physical Performance: Enhances exercise capacity and counters age-related frailty; old mice ran 2× longer on treadmill tests[4][7].
  • Organ Protection: Reduces liver fat accumulation, improves cardiac function, and may support cognitive function in preliminary studies[2][7].
  • Bone & Immunity: Promotes osteoblast activity, inhibits osteoclast formation; modulates immune aging and protects pancreatic islet cells in autoimmune diabetes models[5][10].
  • Safety: No adverse effects reported in preclinical studies; human tolerability unknown. A modified analog (CB4211) showed good tolerability in a Phase 1 trial[7].

Note: These benefits have been demonstrated only in controlled research settings (mice or cells). Translation to humans requires clinical studies.

Lifestyle Factors

Complementary strategies for best outcomes based on MOTS-c’s metabolic mechanisms.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling[4][8].
  • Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
  • Consider intermittent fasting or caloric restriction, which may synergize with MOTS-c’s AMPK-mediated effects.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[9][11]:

  • Clean the vial stopper and skin with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 90° (45° if very lean) into subcutaneous tissue[11].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily over a few seconds[9].
  • Withdraw needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
  • Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and lipohypertrophy[11].
  • Dispose of used syringes immediately in a proper sharps container (never reuse needles)[11].

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-c is an experimental compound; no clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.

References


  • Cell Metabolism (2015)
    — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)
    View Source

  • Journal of Translational Medicine (2023)
    — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)
    View Source

  • Journal of Molecular Medicine (2019)
    — MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.)
    View Source

  • Nature Communications (2021)
    — MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)
    View Source

  • Frontiers in Physiology (2023)
    — Role of MOTS-c in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)
    View Source

  • International Journal of Molecular Sciences (2022)
    — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases (Mohtashami Z, Singh MK, Salimiaghdam N, et al.)
    View Source

  • Cognitive Vitality Reports (2021)
    — MOTS-c (Cognitive Vitality Profile) – Alzheimer’s Drug Discovery Foundation (ADDF)
    View Source

  • USADA Spirit of Sport (2023)
    — What is the MOTS-c peptide? – U.S. Anti-Doping Agency education article
    View Source

  • CDC Vaccine Administration Guidelines
    — Subcutaneous route technique (angle, site selection, no aspiration)
    View Source

  • Experimental & Molecular Medicine (2025)
    — Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Kong BS, Lee H, L’Yi S, et al.)
    View Source

  • MedlinePlus Medical Encyclopedia (2023)
    — Subcutaneous (SQ) injections – Patient instructions for proper technique
    View Source

  • Subcutaneous Drug Injection Review (PMC)
    — Literature review of factors influencing subcutaneous injection pharmacology
    View Source

  • Pure Lab Peptides
    — MOTS-C (20 mg) product page (quality and batch documentation)
    View Source